Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost ...
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Insider Monkey on MSN9d
Is Gilead Sciences (GILD) Among Billionaire Steve Cohen’s Top Stock Picks?We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is ...
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback